vs
Natural Grocers by Vitamin Cottage, Inc.（NGVC）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Natural Grocers by Vitamin Cottage, Inc.的季度营收约是Pacira BioSciences, Inc.的1.9倍（$335.6M vs $177.4M），Natural Grocers by Vitamin Cottage, Inc.净利率更高（3.4% vs 1.6%，领先1.7%），Pacira BioSciences, Inc.同比增速更快（5.0% vs 1.6%），过去两年Natural Grocers by Vitamin Cottage, Inc.的营收复合增速更高（4.4% vs -0.2%）
Natural Grocers by Vitamin Cottage, Inc.是美国本土的特色零售连锁企业，主营认证有机食品、膳食补充剂、天然个护及环保家居类产品，面向健康意识较强的消费群体，门店覆盖美国多州，执行严格品控标准，拒绝售卖含人工添加剂的商品。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
NGVC vs PCRX — 直观对比
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $335.6M | $177.4M |
| 净利润 | $11.3M | $2.9M |
| 毛利率 | 29.5% | — |
| 营业利润率 | 4.4% | 3.9% |
| 净利率 | 3.4% | 1.6% |
| 营收同比 | 1.6% | 5.0% |
| 净利润同比 | 14.0% | — |
| 每股收益（稀释后） | $0.49 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $177.4M | ||
| Q4 25 | $335.6M | $196.9M | ||
| Q3 25 | $336.1M | $179.5M | ||
| Q2 25 | $328.7M | $181.1M | ||
| Q1 25 | $335.8M | $168.9M | ||
| Q4 24 | $330.2M | $187.3M | ||
| Q3 24 | $322.7M | $168.6M | ||
| Q2 24 | $309.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $11.3M | — | ||
| Q3 25 | $11.8M | $5.4M | ||
| Q2 25 | $11.6M | $-4.8M | ||
| Q1 25 | $13.1M | $4.8M | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.0M | $-143.5M | ||
| Q2 24 | $9.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 29.5% | 79.5% | ||
| Q3 25 | 29.5% | 80.9% | ||
| Q2 25 | 29.9% | 77.4% | ||
| Q1 25 | 30.3% | 79.7% | ||
| Q4 24 | 29.9% | 78.7% | ||
| Q3 24 | 29.6% | 76.9% | ||
| Q2 24 | 29.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 4.4% | 1.2% | ||
| Q3 25 | 4.6% | 3.5% | ||
| Q2 25 | 4.7% | 4.7% | ||
| Q1 25 | 5.2% | 1.2% | ||
| Q4 24 | 4.0% | 13.2% | ||
| Q3 24 | 3.7% | -82.8% | ||
| Q2 24 | 4.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.5% | 3.0% | ||
| Q2 25 | 3.5% | -2.7% | ||
| Q1 25 | 3.9% | 2.8% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 2.8% | -85.1% | ||
| Q2 24 | 3.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.49 | $0.05 | ||
| Q3 25 | $0.51 | $0.12 | ||
| Q2 25 | $0.50 | $-0.11 | ||
| Q1 25 | $0.56 | $0.10 | ||
| Q4 24 | $0.43 | $0.38 | ||
| Q3 24 | $0.38 | $-3.11 | ||
| Q2 24 | $0.40 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.2M | $144.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $220.0M | $653.9M |
| 总资产 | $668.6M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $144.3M | ||
| Q4 25 | $23.2M | $238.4M | ||
| Q3 25 | $17.1M | $246.3M | ||
| Q2 25 | $13.2M | $445.9M | ||
| Q1 25 | $21.2M | $493.6M | ||
| Q4 24 | $6.3M | $484.6M | ||
| Q3 24 | $8.9M | $453.8M | ||
| Q2 24 | $13.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $220.0M | $693.1M | ||
| Q3 25 | $212.4M | $727.2M | ||
| Q2 25 | $202.5M | $757.8M | ||
| Q1 25 | $193.0M | $798.5M | ||
| Q4 24 | $181.9M | $778.3M | ||
| Q3 24 | $174.3M | $749.6M | ||
| Q2 24 | $167.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $668.6M | $1.3B | ||
| Q3 25 | $670.5M | $1.3B | ||
| Q2 25 | $659.0M | $1.5B | ||
| Q1 25 | $664.6M | $1.6B | ||
| Q4 24 | $648.9M | $1.6B | ||
| Q3 24 | $655.5M | $1.5B | ||
| Q2 24 | $654.4M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.1M | — |
| 自由现金流经营现金流 - 资本支出 | $11.6M | — |
| 自由现金流率自由现金流/营收 | 3.4% | — |
| 资本支出强度资本支出/营收 | 2.9% | — |
| 现金转化率经营现金流/净利润 | 1.86× | — |
| 过去12个月自由现金流最近4个季度 | $42.6M | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $21.1M | $43.7M | ||
| Q3 25 | $15.6M | $60.8M | ||
| Q2 25 | $2.9M | $12.0M | ||
| Q1 25 | $34.1M | $35.5M | ||
| Q4 24 | $2.7M | $33.1M | ||
| Q3 24 | $24.5M | $53.9M | ||
| Q2 24 | $12.4M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $11.6M | $43.5M | ||
| Q3 25 | $7.5M | $57.0M | ||
| Q2 25 | $-4.2M | $9.3M | ||
| Q1 25 | $27.6M | $26.9M | ||
| Q4 24 | $-6.9M | $31.0M | ||
| Q3 24 | $18.0M | $49.8M | ||
| Q2 24 | $3.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 22.1% | ||
| Q3 25 | 2.2% | 31.7% | ||
| Q2 25 | -1.3% | 5.1% | ||
| Q1 25 | 8.2% | 15.9% | ||
| Q4 24 | -2.1% | 16.6% | ||
| Q3 24 | 5.6% | 29.6% | ||
| Q2 24 | 1.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 0.1% | ||
| Q3 25 | 2.4% | 2.2% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 1.9% | 5.1% | ||
| Q4 24 | 2.9% | 1.1% | ||
| Q3 24 | 2.0% | 2.4% | ||
| Q2 24 | 2.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.86× | — | ||
| Q3 25 | 1.32× | 11.20× | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 2.60× | 7.37× | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 2.72× | — | ||
| Q2 24 | 1.35× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NGVC
| Grocery | $243.8M | 73% |
| Dietary Supplements | $60.7M | 18% |
| Manufactured Product Other | $31.0M | 9% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
